Figure 7.

A flow chart illustrating a therapy-oriented morphomolecular approach to atypical dermal-based tumorigenic melanocytic neoplasms. Of paramount importance are: i) the distinction between melanocytomas (recognized as such by specific genetic signatures) and melanocytic tumors of uncertain malignant potential (MEL.T.U.M.P.; provisionally defined as tumors with unknown driver mutations); ii) among melanocytomas, the distinction between low-grade and high-grade tumors; iii) among MELTUMP, the distinction between tumors with a low tumor mutation burden and tumors with a a high tumor mutation burden, the latter being best managed as per “classical” melanoma.